The DOI matches its Crossref record; 44 of the 47 references it cites were found in a registry or an index.
The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance
Abstract
The fibroblastic element of the tumor microenvironment has been of great interest to cancer biologists but less so to cancer immunologists. Yet, the sharing of a common mesenchymal cell type in the stroma of tumors and at sites of chronic inflammatory lesions, some of which have an autoimmune basis, has been a strong hint that this cellular component of the tumor microenvironment may have an immunologic function. Recent studies have confirmed this possibility. These fibroblast-like cells, which are termed carcinoma-associated fibroblasts (CAF), can be identified by their expression of the membrane protein, fibroblast activation protein-α (FAP). The conditional depletion of the FAP+ CAF permits immune control not only of an artificial, transplanted tumor, but also of an autochthonous model of pancreatic ductal adenocarcinoma (PDA) that replicates the molecular, histologic, clinical, and immunologic characteristics of the human disease. Immune suppression by the FAP+ CAF is mediated by CXCL12, the chemokine that binds to cancer cells and excludes T cells by a mechanism that depends on signaling by the CXCL12 receptor CXCR4. Inhibition of CXCR4 leads to the elimination of cancer cells by enabling the rapid, intratumoral accumulation of preexisting, PDA-specific CD8+ T cells, and reveals the antitumor efficacy of the T-cell checkpoint antagonist anti–PD-L1. Recent studies have also shown that the FAP+ CAF is related to FAP-expressing stromal cells of normal tissues, demonstrating that cancers recruit a member of an essential stromal cell lineage that is involved not only in wound repair but also in normal tissue homeostasis. These findings extend the concept introduced by cancer biologists that the fibroblastic component of tumors has a critical role in the adaptation of the cancer to the host. Cancer Immunol Res; 2(3); 187–93. ©2014 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the consensus is that the predominant effect of CAFs is immunosuppressive with IL-6, CXC-chemokine ligand 9 (CXCL9) and TGFβ having well-established roles in reducing T cell responses116.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [116]
In the citing paper
“CAFs show characteristics of activated fibroblasts and/or myofibroblasts, consistent with the chronic inflammation and mechanical tension in tumors12,233,234.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [233]
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 6×
“Colorectal 0/94 (3, 4) Yes (8) Yes (34) Yes (28)”
BackgroundInfluentialSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 4×
“30; Table 1), raising the possibility of a shared mechanism for the resistance of these three human cancers to anti–PD-1/ anti–PD-L1 (3, 4).”
BackgroundInfluentialCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“assumption that the host immune response rapidly selects for cancer cells that are not immunogenic, thereby enabling cancer to escape immune control (6).”
BackgroundMacrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 1×
“myeloid-derived cells with immune-suppressive function may modify the tumor microenvironment by expressing enzymes, such as nitric oxide synthase 2 and indoleamine 2,3-dioxygenase 1 (IDO1), that interfere with local immune reactions (10– 12), whereas M2-polarized macrophages produce immunesuppressive cytokines, such a…”
BackgroundAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 6×
“Adenocarcinomas that are resistant to a T-cell checkpoint antagonist and exhibit tumoral FAPþ cells, CXCL12, and intraepithelial T-cell exclusion Cancer Response to aPD-1/PD-L1 FAPþ cells present CXCL12 on cancer cells T cells absent from cancer cell nests PDA (mouse) 0/8 (23) Yes (23) Yes (23) Yes (23) PDA 0/14 (4) Y…”
BackgroundInfluentialNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 1×
“hematologic malignancies (1), suggesting that the microenvironments of solid tumors may have unique impediments to the functions of effector T cells.”
Background
Cited by
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863
Self-citationFibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
Therapeutic developments in pancreatic cancer: current and future perspectives
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0005-x · Cited by 1,170
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Metadata
- Authors
- Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Fearon, Douglas T.
- ORCID
- Fearon, Douglas T.
- Venue
- Cancer Immunology Research
- Published
- 2014-03-01
- Volume
- 2
- Issue
- 3
- Pages
- 187-193
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- OpenAlex
- W2144325011
- Cited by
- 288
- References
- 47
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 34 · 2023: 30 · 2022: 38 · 2021: 30 · 2020: 27 · 2019: 22 · 2018: 23 · 2017: 17 · 2016: 17 · 2015: 12 · 2014: 3
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (22310)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- cancer-associated fibroblasts, fibroblast activation protein, tumor microenvironment, immune evasion, CXCL12, CXCR4, pancreatic ductal adenocarcinoma, CD8+ T cells, PD-L1 inhibitors, tumor stroma, chronic inflammation, autoimmunity, T cell checkpoint
- MeSH terms
- Fibroblast Activation Protein Alpha, Animals, Fibroblasts, Humans, Membrane Proteins, Neoplasms, Experimental, Pancreatic Neoplasms, Endopeptidases, Serine Endopeptidases, Stromal Cells, Gelatinases, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Tumor Escape, Receptors, CXCR4, Carcinoma, Pancreatic Ductal, Mice, Chemokine CXCL12, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance. https://app.cochat.ai/papers/10.1158/2326-6066.cir-14-0002
- The paper
- Fearon, D. T. (2014). The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-14-0002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.